A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment

Döhner, 2015, Acute Myeloid Leukemia, N. Engl. J. Med., 373, 1136, 10.1056/NEJMra1406184 Stirewalt, 2003, The role of FLT3 in haematopoietic malignancies, Nat. Rev. Cancer, 3, 650, 10.1038/nrc1169 Daver, 2017, FLT3 inhibition in acute myeloid leukaemia, Lancet Oncol., 18, 988, 10.1016/S1470-2045(17)30509-0 Ambinder, 2021, Potential targeting of FLT3 acute myeloid leukemia, Haematologica, 106, 671, 10.3324/haematol.2019.240754 Papaemmanuil, 2016, Genomic Classification and Prognosis in Acute Myeloid Leukemia, N. Engl. J. Med., 374, 2209, 10.1056/NEJMoa1516192 Ley, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N. Engl. J. Med., 368, 2059, 10.1056/NEJMoa1301689 Prokocimer, 2017, Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy, Blood, 130, 699, 10.1182/blood-2017-02-763086 Quintás-Cardama, 2017, p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status, Leukemia, 31, 1296, 10.1038/leu.2016.350 Bueso-Ramos, 1993, The human MDM-2 oncogene is overexpressed in leukemias, Blood, 82, 2617, 10.1182/blood.V82.9.2617.2617 Pan, 2017, Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy, Cancer Cell, 32, 748, 10.1016/j.ccell.2017.11.003 Andreeff, 2016, Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia, Clin. Cancer Res., 22, 868, 10.1158/1078-0432.CCR-15-0481 Seipel, 2018, MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin, Haematologica, 103, 1862, 10.3324/haematol.2018.191650 Li, 2020, Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia, Signal Transduct. Targeted Ther., 5, 21, 10.1038/s41392-020-0108-z Zhang, 2022, GATM-Mediated Creatine Biosynthesis Enables Maintenance of FLT3-ITD-Mutant Acute Myeloid Leukemia, Mol. Cancer Res., 20, 293, 10.1158/1541-7786.MCR-21-0314 Bjelosevic, 2021, Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia, Cancer Discov., 11, 1582, 10.1158/2159-8290.CD-20-0738 Tyner, 2018, Functional genomic landscape of acute myeloid leukaemia, Nature, 562, 526, 10.1038/s41586-018-0623-z Tang, 2008, Acetylation is indispensable for p53 activation, Cell, 133, 612, 10.1016/j.cell.2008.03.025 Kwon, 2017, p53 stability is regulated by diverse deubiquitinating enzymes, Biochim. Biophys. Acta Rev. Canc, 1868, 404, 10.1016/j.bbcan.2017.08.001 Yuan, 2010, USP10 regulates p53 localization and stability by deubiquitinating p53, Cell, 140, 384, 10.1016/j.cell.2009.12.032 Lin, 2012, Transcriptional amplification in tumor cells with elevated c-Myc, Cell, 151, 56, 10.1016/j.cell.2012.08.026 Liang, 2018, Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy, Cell, 175, 766, 10.1016/j.cell.2018.09.027 Welch, 2016, TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes, N. Engl. J. Med., 375, 2023, 10.1056/NEJMoa1605949 Steensma, 2015, Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes, Blood, 126, 9, 10.1182/blood-2015-03-631747 Sperling, 2017, The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia, Nat. Rev. Cancer, 17, 5, 10.1038/nrc.2016.112 Wong, 2015, Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia, Nature, 518, 552, 10.1038/nature13968 Long, 2020, FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia, Blood, 135, 1472, 10.1182/blood.2019003538 Kim, 2007, Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells, Br. J. Haematol., 138, 603, 10.1111/j.1365-2141.2007.06696.x Tsai, 2012, Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells, Cancer Res., 72, 2622, 10.1158/0008-5472.CAN-11-3605 Wingelhofer, 2018, Pharmacologic inhibition of STAT5 in acute myeloid leukemia, Leukemia, 32, 1135, 10.1038/s41375-017-0005-9 Ji, 2011, Cell-type independent MYC target genes reveal a primordial signature involved in biomass accumulation, PLoS One, 6, 10.1371/journal.pone.0026057 Ko, 2018, Oncogene-induced senescence mediated by c-Myc requires USP10 dependent deubiquitination and stabilization of p14ARF, Cell Death Differ., 25, 1050, 10.1038/s41418-018-0072-0 Liu, 2011, Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13, Cell, 147, 223, 10.1016/j.cell.2011.08.037 Ogawara, 2002, Akt enhances Mdm2-mediated ubiquitination and degradation of p53, J. Biol. Chem., 277, 21843, 10.1074/jbc.M109745200 Halaschek-Wiener, 2004, Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells, Cell. Signal., 16, 1319, 10.1016/j.cellsig.2004.04.003 Pei, 2020, FLT3 Inhibitors Induce Instability of p53 By Mir-181 Mediated Downregulation of Deubiquitinase YOD1 in Acute Myeloid Leukemia, Blood, 136, 6, 10.1182/blood-2020-139002